Energy

Industry Auto Home

Biotech Healthcare

Pharmaceuticals

Banking/Finance

Cons. Products

Ind'l Goods/Sys

Healthcare/Biotech Services

More

INVEST FROM INDIA 7% ROI IN DUBAI\*





Business News > Industry > Healthcare/Biotech > Pharmaceuticals > Supreme Court asks drugs advisory body to decide fate of over 334 banned combinal Search for News, Stock Quotes & NAV's

You tried accessing the mobile version of Economic Times from a non-mobile device. We feel this desktop version suits your device better. Take me back to the Mobile Version

11:18 AM | 23 OCT MARKET STATS ▼ सैंसेक्स **34.012** ▼ -121.76

निफ्टी 50 **10.195 v** -49.70 सोना (एमसीएक्स) (₹/10 ... **32,016.00 \( \Limes\)** 122.00

युएसडी/भारतीय ... **73.78 \( \)** 0.21 पोर्टफोलियो बनाएं

**SPOTLIGHT** 

Equity»Multi Cap

**Direct- Growth** 

**BUY NOW** 

3M

-3.59

ई-टी मार्केट एप डाउनलोड करें

CHOOSE LANGUAGE HIN

Sponsored

3Yrs

11 78

# Supreme Court asks drugs advisory body to decide fate of over 334 banned combination medicines

By Prabha Raghavan, ET Bureau | Updated: Dec 15, 2017, 12.31 PM IST

Comments





FDCs are cocktail drugs that contain two or more therapeutic ingredients packed in a single dose.

NEW DELHI: The Supreme Court has asked the country's technical advisory body on drugs to decide on the fate of more than 300 combination medicines banned by the government between March 2016 and June 2017. The order is a potential relief to drug makers who have argued that the government did not consult statutory bodies provided for in the country's drug regulations before banning these drugs.

Companies can make and sell the 349 contested fixed dose combination drugs

(FDCs) while Drugs Technical Advisory Board (DTAB) deliberates on the issue.

At the same time, the court also clarified that this order is specific to two of the government's ban notifications due to "peculiar facts" of the cases.

In an order dictated in open court on two government notifications banning these FDCs, a Supreme Court bench of Justices Rohinton Fali Nariman and Sanjay Kishan Kaul on Thursday said it was setting aside the ban on 15 such drugs which were manufactured in India before 1988.

However, if it chooses to, the government can carry out further inquiry on whether these drugs should continue to be marketed in the country, the court suggested.

For the remaining 334 FDCs, the court suggested that DTAB should decide whether the manufacture and sale of these drugs should be regulated, restricted or outright banned, and submit a report with its recommendations to the government within six months.



combination medicines

SBL Syzygium Jambolanum Mother Tincture Q



किसी भी आहार के बिना वजन कम करने के लिए आसान

curbs on antibiotics sale without

vaccine combos?

Get Your Listing on Economic Times

Are you an Advertising & Marketing Agency?

Mirae Asset India Equity Fund

-2.85

-0.95

gout attacks drug

Figures in %

For regulatory disclaimers, click here.

तरीका Supreme Court asks drugs advisory body PIL filed in Bombay High Court seeking Are companies bribing doctors to push Zvdus Cadila gets USFDA noc to decide fate of over 334 banned

The bench will pronounce its official judgment on Friday.

FDCs are cocktail drugs that contain two or more therapeutic ingredients packed in a single dose.

While 344 of the contested drugs are currently available in the market as the Delhi High Court in December last quashed the ban on them imposed in March last year, the other five FDCs banned in June, too, can now return to the market.

The Supreme Court bench said DTAB or a sub-committee it sets up should hear arguments by the drug industry as well as patient group All India Drug Action Network (AIDAN), which is in favour of the ban notifications, before preparing its report.

The government is expected to carefully consider this report, "apply its mind" and accordingly either maintain or modify its ban notifications, according to it.

The Kokate committee — the government's expert committee that had studied the FDCs and declared them "irrational" — was not clear as to the reasoning behind its decision, it observed.

The top court last month said the government does not have to consult statutory bodies like DTAB before banning FDCs as such consultations were not specified in Section 26A of the Drugs and Cosmetics Act. The government had used Section 26A, which defines its power to regulate the manufacture and sale of drugs "in public interest", to ban these drugs last year on a separate expert committee's recommendation.

"The judgment means that the government need not mandatorily consult DTAB to prohibit the manufacture and sale of FDCs it finds irrational and can use expert committees like the Kokate committee," said S Srinivasan, a member of AIDAN. "Earlier, the Delhi High Court had quashed the ban only on the reasoning that DTAB was not consulted, but now the government has been empowered to act fast," he said. "The only drawback is that six months seems too short a deadline to achieve all this," he added.

AIDAN's counsel Colin Gonsalves told the court on Thursday that there are 40,000 contested and debated FDCs in India, while any well-regulated country allows 500 FDCs at most.

Lawyers representing drug makers said the decision is a victory for the industry.

"The court has referred the matter for a fresh look to decide if the drugs require to be banned under Section 26A of the Drugs & Cosmetics Act," said Ashish Prasad, partner at Economic Laws Practice, who represented Indian Drug Manufacturers Association (IDMA), Federation of Pharma Entrepreneurs (FOPE) and Confederation of Indian Pharmaceutical Industries (CIPI) during the proceedings.

Archana Sahadeva, associate partner at Singh & Singh Law Firm, who represented drug makers such as Cipla, MacLeods, Alembic and Microlabs, said, "This means that the process will now be more transparent."

The 300 plus contested drugs include popular brands such as Corex, Phensedyl, D'Cold Total, Vicks Action 500 Extra and Saridon.

Most Read

Most Shared

Most Commented

Worst accident caused by trespassing in history of railways

Petrol, diesel prices slashed further on Dussehra

How car ownership is changing rapidly and irreversibly in India

Reliance Jio 4G revolution may render the 2G

Tatas not OK with Goval in Jet Airways cockpit.

wants complete control over the airline


feature phone extinct

Mor

## **Industry Top Trending Terms**

Reliance Jio Gigafiber Reliance Industries
Aadhaar Exit Plan Tata Sky DTH
Google Shopping Tab IL&FS Indian Oil
Tata Harrier SUV Indian Railways Plan
Renewable energy Electric Vehicle





Supreme Court asks drugs advisory body to decide fate of over 334 banned combination medicines

PIL filed in Bombay High Court seeking curbs on antibiotics sale without

Are companies bribing doctors to push vaccine combos?

Save

Zydus Cadila gets USFDA noc gout attacks drug

## **Business Listing on Economic Times.**

Ale you a busiliess owliel: Oct Ioul Flee

**Register Now** 



Read more on

**Banned Medicines** 

**FDCs** Supreme Court Combination Drugs

DTAB

## Also Read

Supreme Court to rule on cracker ban today

Arkansas Supreme Court disqualifies term limits proposal

New campaign seeks support for expanded Supreme Court

The Latest: Supreme Court wrestles with immigration case

Supreme Court considering case on detention of immigrants

Comments (1)

Add Your Comments

## From Around The Web

Sponsored by



Get 1+1 on 5 Star buffet -Try 1 month for free

Times Prime



Great Indian Festival - The biggest business saving is here!

Amazon Business



An abode in Greater Noida awaits you at Godrej Park Urban!

Investors Planner



10-minute poker play for 6 digit cash prize! Get 500 to play

Adda52.com

#### More from The Economic Times



FPIs pull out over \$4 billion from markets in 3 weeks

Now, illegal foreign assets under I-T scanner



MPC members raised concerns about inflation



A helping hand for India's 3rd biggest lender

**NEXT STORY** 

# PIL filed in Bombay HC High Court seeking curbs on antibiotics sale without prescription

Are you an Advertising & Marketing Agency? Get Your Listing on Economic Times

CREATE FREE LISTING

ET Bureau | Oct 23, 2018, 07.54 AM IST

0

PIL filed in Bombay High Court seeking curbs on antibiotics sale without

Are companies bribing doctors to push vaccine combos?

Zvdus Cadila gets USFDA noc gout attacks drug

Supreme Court asks drugs advisory body



The court is expected to hear the PIL this week.

High Court seeking a directive to restrict overthe-counter sale of antibiotics in India, the world's "largest consumer of antibiotics".

The petition followed investigation by an activist who found that antibiotics under 'restricted use' were freely available over the counter across pharmacies in India.

Petrol, diesel prices slashed further on Dussehra How car ownership is changing rapidly and irreversibly in India Reliance Jio 4G revolution may render the 2G feature phone extinct Tatas not OK with Goyal in Jet Airways cockpit,

The PIL pointed to the United Nations high-level meeting on antimicrobial resistance and said a UN declaration had asked countries to come up with an action plan to curb the misuse of antibiotics by 2018.

"That the pressure is on India, the world's largest consumer of antibiotics and where carelessness in antibiotic use and environmental antibiotic pollution has been documented," the petition said.

The court is expected to hear the PIL this week.

Antibiotic drugs are part of a nearly Rs 17,000 crore business in India, growing at 5-6% annually.

India is one of the highest consumers of antibiotics. These drugs are also used rampantly in agriculture, specifically for poultry and livestock.

## Are you a Business Owner? Get Your Free **Business Listing on Economic Times.**

**Register Now** 

Restricted Use



Antibiotics

India

## Also Read

Read more on

PILs are for the Poor: Justice Ranjan Gogoi

PIL

PIL seeks Supreme Court's intervention to pass on rate benefits to retail borrowers

Bombay HC High Court

High Court declines PIL against poor telecom signals, call drops

HC refuses to entertain PIL to cancel lease of Kandla Port land to firm

SC adjourns hearing on Rafale deal PIL to October 10

## **Industry Top Trending Terms**

wants complete control over the airline

Reliance Jio Gigafiber Reliance Industries Aadhaar Exit Plan Tata Sky DTH Google Shopping Tab IL&FS Indian Oil Tata Harrier SUV Indian Railways Plan Renewable energy Electric Vehicle

# Why the Tatas want Jet Airways Fixed-dose combinations: India's medical SOS Why can't telcos deliver voice calls properly? GO TO ET PRIME $\rightarrow$

#### From Around The Web

Reach target customers money-making opportunity in across network with Sponsored Content

It's time to win big with Timex Howzzat for an offer. TIMEX

Have this before breakfast to melt belly fat in 4 weeks.

Good Life Nutrition

Sponsored by

Don't miss this biggest

2018

- Supreme Court asks drugs advisory body to decide fate of over 334 banned combination medicines
- PIL filed in Bombay High Court seeking curbs on antibiotics sale without
- Are companies bribing doctors to push vaccine combos?
- Zvdus Cadila gets USFDA noc gout attacks drug



last': Pakistan finance minister



\$600-billion reason why China crash might just worsen



Vajpayee's niece to fight Raman Singh in C'garh



High noon in Brussels: Italy prepares for budget showdown

## **NEXT STORY**

## Are companies bribing doctors to push vaccine combos?

By Rema Nagarajan, TNN | Oct 22, 2018, 10.44 AM IST





Most firms dismiss this as a practice of "fixed margins" on MRP prevalent across pharma and vaccine industries or as "business terms" offered to customers.

A vaccine against five diseases costs Rs 2,800. Add one for a sixth disease, Hepatitis B, to this combination and the price jumps to Rs 3,900 though the Hepatitis B vaccine by itself is just Rs 60. Another vaccine against five diseases including Hepatitis B costs Rs 382, but the addition of a polio vaccine pushes the price up to Rs 2,392 though the standalone injectable polio vaccine (IPV) costs just about Rs 400 in the open market.

Paediatricians question these huge price increases with the addition of just one more

vaccine. Vaccine companies' spokespersons say it is because adding a component makes the manufacturing process more complex.

What makes this a real problem is that the standalone IPV is not available any more, forcing paediatricians to buy the combination vaccine. Earlier, two brands of standalone IPV were available in India, Erapol from Biological Evans and Imovax from Sanofi, for Rs 400. Sanofi told TOI IPV was not available in the open market because of a global shortage. Sanofi supplies the standalone IPV to the immunisation programme at Rs 172.

A dose of Easy Five vaccine from Panacea Biotec, against diphtheria, pertussis, tetanus, pneumonia and hepatitis, costs Rs 382 in the open market as it's under price control. However, Easy Six, which includes all vaccines in Easy Five plus IPV, costs parents Rs 2,392, Rs 1,610 more than when the two are given separately.

While companies claim the extra cost is due to the complexity of manufacturing combination vaccines, whether it is Pentaxim or Hexaxim, the maximum retail price leaves

Supreme Court asks drugs advisory body to decide fate of over 334 banned combination medicines

PIL filed in Bombay High Court seeking curbs on antibiotics sale without

Are companies bribing doctors to push vaccine combos?

Zvdus Cadila gets USFDA nod gout attacks drug

Are you an Advertising & Marketing Agency? Get Your Listing on Economic Times

CREATE FREE LISTING

Most Read

Most Shared

Most Commented

Worst accident caused by trespassing in history of railwavs

Petrol, diesel prices slashed further on Dussehra

How car ownership is changing rapidly and irreversibly in India

Reliance Jio 4G revolution may render the 2G feature phone extinct

Tatas not OK with Goyal in Jet Airways cockpit, wants complete control over the airline

More »

## **Industry Top Trending Terms**

Reliance Jio Gigafiber Reliance Industries Aadhaar Exit Plan Tata Sky DTH Google Shopping Tab IL&FS Indian Oil Tata Harrier SUV Indian Railways Plan Renewable energy Electric Vehicle

Injectable Polio Vaccine

Sponsored by

diseases at Ks 2,392, over Ks 4/5 goes as incentive to doctors or nospitals. Most firms dismiss this as a practice of "fixed margins" on MRP prevalent across pharma and vaccine industries or as "business terms" offered to customers. But of course, it's the person who decides which product to choose - the doctor or hospital -- who gets to pocket the incentive, while the baby's parents pay the MRP.

(This article was originally published in The Times of India)

0 Comments

Roseola

Are you a Business Owner? Get Your Free **Business Listing on Economic Times.** 

**Register Now** 

Pneumonia

Hepatitis B Vaccine

Pharmaceutical Industry

## SigTuple: AI for blood tests Why ONGC's long list of discoveries is only a matter of owner's pride Ask, and ye shall receive: The progress report is in for banking chatbots

GO TO ET PRIME →


From Around The Web

Read more on

1mg.com

1yr-old with cancer wont SBL Syzygium Jambolanum This festive season, own the Abandoned by husband, I'm Mother Tincture Q make it to next B'day without BMW X1. struggling to save my dying help Son. BMW India Milaap KETTO

#### More from The Economic Times



**NEXT STORY** 

# Zydus Cadila gets USFDA nod for generic gout attacks drug

Are you an Advertising & Marketing Agency? **Get Your Listing on Economic Times** 

Supreme Court asks drugs advisory body to decide fate of over 334 banned combination medicines

PIL filed in Bombay High Court seeking curbs on antibiotics sale without prescription

Are companies bribing doctors to push vaccine combos?

Zvdus Cadila gets USFDA noc gout attacks drug



The drug is used to prevent or treat attacks of gout, a condition caused by high uric acid levels in the blood. The medication is also used to treat familial Mediterranean fever.

NEW DELHI: Drug firm Zydus Cadila Thursday said it has received a tentative nod to market generic Colchicine tablets used for prevention and treatment of gout attacks in US market.

The company has received the tentative approval from the United States Food and Drug Administration (USFDA) to market Colchicine tablets USP in the strength of 0.6 mg, Zydus Cadila said in a statement.

The product is the generic version of Colcyrs tablets in the same strength, it added.

Most Read Worst accident caused by trespassing in history of Petrol, diesel prices slashed further on Dussehra How car ownership is changing rapidly and irreversibly in India Reliance Jio 4G revolution may render the 2G feature phone extinct Tatas not OK with Goyal in Jet Airways cockpit, wants complete control over the airline Mor

Most Shared

Most Commented


## **Industry Top Trending Terms**


Reliance Jio Gigafiber Reliance Industries Aadhaar Exit Plan Tata Sky DTH Google Shopping Tab IL&FS Indian Oil Tata Harrier SUV Indian Railways Plan Renewable energy Electric Vehicle

The tablets, "will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad," it said.

The drug is used to prevent or treat attacks of gout, a condition caused by high uric acid levels in the blood. The medication is also used to treat familial Mediterranean fever.

The group now has 223 approvals and has so far filed over 330 abbreviated new drug





## From Around The Web

Laurus Labs climbs 6% on USFDA approval Lupin gets EIR from USFDA for Nagpur facility



Supreme Court asks drugs advisory body to decide fate of over 334 banned combination medicines

PIL filed in Bombay High Court seeking curbs on antibiotics sale without

Are companies bribing doctors to push vaccine combos?

Zvdus Cadila gets USFDA noc gout attacks drug



MHA prescribes visa care for 12 stock ideas that can foreign patients



deliver decent gains over 3



FinMin extends deadline for Sept GST returns



Modi: Rahul Gandhi

## **NEXT STORY**

# DCGI asks company to recall Ozurdex Intravitreal implants

PTI | Oct 16, 2018, 07.43 PM IST

The silicone sleeve is an intrinsic part of the Ozurdex product and the particle is not an external contaminant. The Drug Controller General of India (DCGI) has asked a pharmaceutical company to recall one of its products, Ozurdex Intravitreal Implant, a steroid eye implant for macular

edema, after the company admitted that a silicone particle has been detected in it. During a routine manufacturing inspection, a silicone particle, approximately 300 microns in diameter, was observed in dispensed Ozurdex implants, a statement by the Allergan India Private Limited said.

The silicone particle has been confirmed to originate from the needle sleeve.

The silicone sleeve is an intrinsic part of the Ozurdex product and the particle is not an external contaminant, it said.

Batches of Ozurdex already distributed in India are affected by this defect. Generally, most batches have 2 to 4 per cent defective units, but defect rates as high as 22 per cent have been reported, the company statement said.

"Ozurdex batches known to be affected are being recalled from the Indian market. New stocks of Ozurdex that are reliably known to be free of this defect will be made available in India and Allergan will provide an update when new stocks will be available for each market," it said.

Until unaffected product is available, clinicians are advised to consider alternative treatments.

Allergan has identified a corrective action that eliminates creation of the particle and is working quickly to implement this action prior to releasing any further product in agreement Are you an Advertising & Marketing Agency? Get Your Listing on Economic Times

CREATE FREE LISTING

Most Read

Most Shared

Most Commented

Worst accident caused by trespassing in history of

Petrol, diesel prices slashed further on Dussehra

How car ownership is changing rapidly and irreversibly in India

Reliance Jio 4G revolution may render the 2G feature phone extinct

Tatas not OK with Goyal in Jet Airways cockpit, wants complete control over the airline

More »

## **Industry Top Trending Terms**

Reliance Jio Gigafiber Reliance Industries Aadhaar Exit Plan Tata Sky DTH Google Shopping Tab IL&FS Indian Oil Tata Harrier SUV Indian Railways Plan Renewable energy Electric Vehicle

Supreme Court asks drugs advisory body PIL filed in Bombay High Court seeking curbs on antibiotics sale without

Are companies bribing doctors to push vaccine combos?

Zvdus Cadila gets USFDA nod gout attacks drug

A separate communication is also being sent to hospitals providing details of the recall process, it added.

0

Are you a Business Owner? Get Your Free **Business Listing on Economic Times.** 

**Register Now** 

SigTuple: AI for blood tests

ONGC's many discoveries are just owner's pride



The progress report is in for banking chatbots



Allergan, Plc

New Delhi

Ozurdex Intravitreal

Diabetic Retinopathy

GO TO ET PRIME  $\rightarrow$ 

Read more on

DCGI

From Around The Web

Join thousands of lenders. Make returns upto 25%. Try P2PI

Faircent

increase your wealth

Sponsored by



Be a professional trader and 1yr-old with cancer won't make it to next B'day without help

#### More from The Economic Times



SBL Syzygium Jambolanum

Mother Tincture Q

1mg.com

spoilsport for Indian startups Tata chief

How regulations are playing The job just got tougher for

may hit \$9.6 bn in 2022:

Medical technology sector Report

Number of crorepatis up by 60% in India

Get a Quote

Type Company Name

Get Quote

**Browse Companies** 

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z | 1 2 3 4 5 6 7 8 9

**Browse Mutual Funds** 

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

# **RELIANCE RETAIL'S SUCCESS:**

Know the deceptively simple formula

Powered by

Live Market News

Portfolio

Mobile Live TV **Biz Listings**  Industry **Newsletters** 

Commodities Speed

Blogs RSS

Download it from

APP STORE

About Us

Create Your Own Ad Advertise with Us

Terms of Use & Grievance Redressal

Privacy policy

Download it from

**GOOGLE PLAY** 

**FOLLOW US** 

PIL filed in Bombay High Court seeking curbs on antibiotics sale without

Are companies bribing doctors to push vaccine combos?

Zvdus Cadila gets USFDA noc gout attacks drug

Download it from

Windows Store

Supreme Court asks drugs advisory body to decide fate of over 334 banned combination medicines

prescription

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sc-asks-drugs-advisory-body-to-decide-fate-of-349-banned-combi... 9/10

Other Times Group news sites

इकर्नोमिक टाइम्स| ઇડीनो.मि.५ टाईम्स | Pune Mirror | Bangalore Mirror | Ahmedabad Mirror | ItsMyAscent | Education Times | Brand Capital | Mumbai Mirror | Times Now | Indiatimes | नवभारत टाइम्स | महाराष्ट्र टाइम्स | ವಿಜಯ ಕರ್ನಾಟಕ | Go Green | AdAge India | Eisamay | IGN India | NavGujarat Samay | Times of India | Samayam Tamil | Samayam Telugu | Miss Kyra | Bombay Times | Filmipop | Games App | MX Player

#### Living and Entertainment

Timescity| iDiva | Entertainment | Zoom | Healthmeup | Luxpresso | Gadget Reviews | Titanium & Platinum Credit Card | Online Songs | MensXP | Hotels | Travel Destinations | Cricbuzz | Recipes | Gaana | Happytrips | Getsmartapp

Interest Network

itimes

Hot on the Web

Share Market | GST | Income Tax Slabs | Aadhaar Card | IFSC Code | Mutual Funds |
Top ELSS Funds to Invest | How to save Income Tax | Sensex Today | Nifty Bank |
Telangana Assembly Election | Income Tax Calculator

#### Services

Book print ads| Online shopping | Matrimonial | Astrology | Jobs | Tech Community |
Property | Buy car | Bikes in India | Free Classifieds | Send money to India | Used Cars |
Restaurants in Delhi | Remit to India | Buy Mobiles | Listen Songs | News |
TimesMobile | Real Estate Developers | Restaurant Deals in Delhi | Car Insurance |
Gadgets Now | Free Business Listings | CouponDunia | Remit2India | Techradar |
AliveAR | Getsmartapp App | ETMoney Finance App | Feedback | Auto

## In Case You Missed It

All about PNB Fraud Income Tax Calculator

Home Loan Calculator RCom

IL&FS Education Loan Calculator

Income Tax IL&FS crisis
Oil Import IFSC Code

Yes Bank Video Datsun Go, GO+ booking

Copyright © 2018 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service